摘要:
The invention relates to a pigment composition of C.I. Pigment Blue 15:6, containing 0.5% to 15% by weight of an additive of the formula (1), based on the weight of the pigment, in which R1, R2, R3, R4, R5 and R6 independently of one another are hydrogen; C1-C22 alkyl or C2-C22 alkenyl, whose carbon chain in each case may be interrupted by one or more moieties —O—, —S—, NR9—, —CO— or —SO2— and/or may be substituted one or more times by hydroxyl, halogen, aryl, heteroaryl, C1-C4 alkoxy and/or acetyl; C3-C8 cycloalkyl, whose carbon framework may be interrupted by one or more moieties —O—, —S—, —NR10—, —CO— or —SO2— and/or may be substituted one or more times by hydroxyl, halogen, aryl, heteroaryl, C1-C4 alkoxy and/or acetyl; dehydroabietyl or aryl or heteroaryl, with R9 and R10 independently of one another being hydrogen or C1-C22 alkyl. The pigment composition of the invention is produced with application of a wet grinding process, more particularly a salt kneading operation.
摘要:
The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要:
A glass printing ink and glass printing lacquer are prepared, which contain at least one photoinitiator, at least one resin and at least one additional substance. The resin is an epoxy resin based on bisphenol A, diluted in a UV-curing monomer, or a resin with functional groups containing free functional amino, hydroxy, epoxy, acid, acid anhydride and/or acrylate groups, or a combination of the epoxy resin with the resin with functional groups. The at least one additional substance is a wax. The use of the glass printing ink and glass printing lacquer in printing a glass substrate and processes for the printing of a glass substrate are also described.
摘要:
Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
摘要:
The present invention relates to bispecific antibodies against human ErbB-2 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
摘要:
Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
摘要:
Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
摘要:
Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
摘要:
Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.